GSK plc (LON:GSK)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 88.81B +50.6% |
| Revenue (ttm) | 32.67B +4.1% |
| Net Income | 5.72B +122.0% |
| EPS | 1.39 +123.2% |
| Shares Out | 4.01B |
| PE Ratio | 15.95 |
| Forward PE | 12.36 |
| Dividend | 0.72 (3.27%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 408,624 |
| Average Volume | 11,987,935 |
| Open | 2,196.00 |
| Previous Close | 2,214.00 |
| Day's Range | 2,192.00 - 2,211.00 |
| 52-Week Range | 1,242.50 - 2,282.00 |
| Beta | 0.27 |
| RSI | 68.55 |
| Earnings Date | Feb 4, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial StatementsNews
GSK secures Canadian made high blood pressure drug in US$950 million deal
CEO Luke Miels is under pressure to build up GSK’s portfolio before their patent of the HIV drug dolutegravir expires
GSK Expands Pipeline With $950 Million Pulmonary Hypertension Power Play
GSK will acquire 35Pharma for $950 million, adding HS235, a new drug candidate targeting pulmonary hypertension affecting millions worldwide. ... Full story available on Benzinga.com
GSK to Buy 35Pharma for $950 Million
GSK struck a deal to buy Canada's 35Pharma as the U.K. drugmaker seeks to bolster its exposure to diseases linked to obesity.
GSK (GSK) Acquires 35Pharma for $950 Million to Expand RI&I Portfolio
GSK (GSK) Acquires 35Pharma for $950 Million to Expand RI&I Portfolio
GSK To Acquire 35Pharma For $950 Mln
(RTTNews) - GSK plc (GSK, GSK.L, GS71.DE) has entered an agreement to acquire 35Pharma, a Canada-based, private, clinical-stage biopharmaceutical company specialised in the development of protein-base...
GSK to buy 35Pharma for $950 million
GSK on Wednesday agreed to buy Canadian biopharmaceutical company 35Pharma Inc for $950 million in cash.
GSK to acquire Canada's 35Pharma for $950M in cash
35Pharma to be Acquired by GSK to Accelerate Development of HS235, a Potential Best-in-Class Investigational Medicine for Pulmonary Hypertension (PH)
MONTREAL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- 35Pharma, a Canada-based, private, clinical-stage biopharmaceutical company specialised in the development of novel protein-based therapeutics today announc...
GSK Enters $1B Licensing Deal with Frontier Biotechnologies for siRNA Therapies
GSK Enters $1B Licensing Deal with Frontier Biotechnologies for siRNA Therapies
GSK inks licensing deal worth up to $1B with China’s Frontier Bio
GSK (GSK) stock is in focus as the company inks a drug licensing deal worth up to $1B with China's Frontier Biotechnologies for siRNA treatments. Read more here.
Frontier Biotechnologies strikes up to $1 billion deal with GSK
Frontier Biotechnologies said on Tuesday it has struck a deal with GSK , granting the British drugmaker worldwide rights to develop two small interfering RNA therapies targeting kidney diseases in an ...
Bora Pharmaceuticals Signs $250 Mln Five-Year Manufacturing Deal With GSK; Bora Stock Up
(RTTNews) - Bora Pharmaceuticals Co., Ltd. (6472.TW, BORAY), a Taiwan-based international pharmaceutical company, on Monday announced a renewed five-year manufacturing partnership with a pharmaceutica...
Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract.
Biodexa Licenses Phase 1-Ready Drug Candidate From Otsuka For Rare Stomach Cancer
Zinger Key Point: MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (GIST) Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical-stage bi...
GSK's HIV Treatment Achieves Superior Results in Phase III Trial
GSK's HIV Treatment Achieves Superior Results in Phase III Trial
Ex-Dividend Reminder: Shell, Patria Investments and Glaxosmithkline
Looking at the universe of stocks we cover at Dividend Channel, on 2/20/26, Shell plc (Symbol: SHEL), Patria Investments Limited - Class Ahares (Symbol: PAX), and Glaxosmithkline plc (Symbol: GLAXF) w...
GSK's AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows
PHILADELPHIA--(BUSINESS WIRE)--GSK's AREXVY associated with reductions in certain RSV-related risks, real world study shows.
GSK: Post-Pivot Buoyancy Set To Continue After Strong 2025 (Upgrade)
GSK's Arexvy Vaccine Shows Strong Effectiveness in Real-World Study
GSK's Arexvy Vaccine Shows Strong Effectiveness in Real-World Study
GSK says RSV shot Arexvy lowers risk of CV events, asthma, and COPD
GSK says real-world data shows Arexvy cut RSV hospitalizations and lowered heart attack/stroke, asthma and COPD flare-ups in adults 60+. Read more here.
GSK wins approval of Exdensur in Europe for severe asthma
GSK Reports Promising Data for RSV Vaccine Effectiveness
GSK Reports Promising Data for RSV Vaccine Effectiveness
Europe Clears GSK's New Twice-Yearly Asthma Treatment
The European Commission on Tuesday approved GSK plc’s (NYSE: GSK) Exdensur (depemokimab) in two indications, including: As an add-on maintenance treatment for severe asthma with type 2 inflammation, ...
GSK Begins Fourth Tranche Of Up To GBP 0.45 Bln Share Buyback Under GBP 2 Bln Programme
(RTTNews) - British drug major GSK plc (GSK, GSK.L) announced Tuesday that it is commencing the fourth tranche of its 2 billion pounds share buyback Programme announced last year. The company will buy...